Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04446806
Other study ID # APL-01
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date June 1, 2019
Est. completion date May 31, 2021

Study information

Verified date March 2020
Source The First Affiliated Hospital of Soochow University
Contact Suning Chen
Phone 8613814881746
Email chensuning@sina.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

With the introduction of all-trans-retinoic acid (ATRA) and arsenic,the outcome of patients with acute promyelocytic leukemia (APL)has been improved considerably over the last decades.However,early deaths (EDs), mainly due to APL-specific coagulopathy, differentiation syndrome (DS)emerge as a major threat to APL patients.We observe and evaluate the effectivity of induction therapy in patients with APL. Administrate intravenous dexamethasone to prevent or preemptive treat DS. Assess the efficacy and safety of ruxolitinib as second treatment in patients with severe DS with no respond to dexamethasone.Furthermore,the changes of spectrum of cytokines are monitered to find the relationship between the cytokines and the severity of DS.


Description:

Adults ages 18-75 with primary acute promyelocytic leukemia.

Design:

The induction therapy with ATRA 25mg/m2/d and ATO 10mg/kg/d should be started as soon as the diagnosis of APL confirmed.

Intravenous dexamethasone at a dose of 5-20 mg daily must be started if the WBC count greater than 5e+9/L (before or during the treatment with ATRA) as prevention or preemptive therapy of DS.

Idarubicin (4-10 mg/m2 /d*3d) and hydroxyurea(1.0-3.0g/d)can be given as leukocyte lowering therapy which may lessen the risk of DS.

When the progression of clinical symptoms of DS with no response to dexamethasone,ATRA must be stopped and ruxolitinib (5-20mg /d) should be administrated to reduce the production of cytokines.

Participants should stay in the hospital during the treatment for about 4 weeks.

The changes of spectrum of cytokines are monitored to discover the potential relationship between the cytokines and the severity of DS.

Participants will visit every 1 months after CR for 3 years.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date May 31, 2021
Est. primary completion date December 31, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Clinical diagnosis of primary acute promyelocytic leukemia.

- ECOG score=3.

- Must be able to understand and willing to participate in the study and sign the informed consent.

Exclusion Criteria:

- Refractory/secondary acute promyelocytic leukemia.

- Severe complications such as myocardial infarction, chronic cardiac insufficiency, hepatic failure, renal insufficiency, etc.

- Clinically uncontrolled active infections.

- Malignant tumors with other progresses.

- Ecg: QT interval > 450 ms.

- Allergic to arsenic agent.

- Pregnant or lactating women.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ruxolitinib
Ruxolitinib as second treatment in patients with severe DS failed in responding to hormone.Furthermore

Locations

Country Name City State
China First Affiliated Hospital, Soochow University Suzhou Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
The First Affiliated Hospital of Soochow University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary complete remission rate complete remission rate after treated by the induction regimen with ATRA and Arsenite during the induction treatment
Primary incidence and severity of differentiation syndrome All symptoms and signs associated to DS should be paid closely attention to. during the induction treatment
Secondary overall survival from the date of inclusion to date of death, irrespective of cause from the day of first patient treatment up to 36 months after the last patient's enrollment
See also
  Status Clinical Trial Phase
Recruiting NCT04994210 - Sintilimab in Combination With Chidamide in Newly Diagnosed ENKTCL Phase 2
Terminated NCT05247957 - NKG2D CAR-NK Cell Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia N/A
Completed NCT04621123 - Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients Phase 2
Recruiting NCT05140616 - Study of Chidamide for Steroid-resistant/Steroid-dependent Severe cGVHD Phase 1/Phase 2
Recruiting NCT05349552 - Safety and Efficacy of SBRT in the Treatment of Thoracic Malignant Tumors at Different Sites
Completed NCT03820596 - Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCL Phase 1/Phase 2
Completed NCT02018250 - Study to Evaluate the Safety of a New Oxime, MMB4 DIMETHANESULFONATE (DMS) Phase 1
Recruiting NCT05556889 - Safety and Analgesic Efficacy of a Modified Auriculotemporal Nerve Block N/A
Not yet recruiting NCT06244537 - Study on the Safety and Efficacy of MR-Linac Technique in Patients With Unresectable Locally Advanced Colon Cancer N/A
Recruiting NCT03455972 - Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT Phase 1/Phase 2
Completed NCT04785170 - Clinical Study to Evaluate Safety and Efficacy of Amino Acid in Healthy Individuals N/A
Recruiting NCT04677452 - Dose Exploration Study OF JWCAR129, BCMA-Targeted CART for RRMM Phase 1
Completed NCT01305044 - The HEALS Project - Health Education and Active Living for Surviving Seniors Phase 2
Active, not recruiting NCT04646590 - A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19 Phase 3
Recruiting NCT05021276 - Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHD Phase 4
Not yet recruiting NCT05008666 - Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH Phase 2
Recruiting NCT06066840 - Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal Involvement Phase 4
Active, not recruiting NCT04852068 - A Clinical Trial of Freeze-dried Human Rabies Vaccine (Vero Cells) Phase 3